

## Development of candidate compounds for Probe & Catch CAR-T cells targeting CD40-positive hematologic tumors

TICAROS  
THERAPEUTICS  
**TICAROS**

ONCOLOGY	Candidate
Product Type	Gene-modified Cell
Indication	CD40-positive hematologic malignancies (lymphoma, myeloma and AML)
Target	CD40
MoA(Mechanism of Action)	A peptide tag-binding CAR-T cells in combination with an adaptor antibody against CD40, labeled with a peptide tag (CD40 probe) (“Switchable CAR system”).
Competitiveness	<ul style="list-style-type: none"> <li>• CD40 is a well-known hematological tumor antigen, but the efficacy of CD40-targeting antibodies have been poor. Thus, CD40 can be a potential target of CAR-T cells, but has never been considered so, because CD40 is also expressed in various hematological and non-hematological normal tissues, raising the concern of on-target off-tumor toxicity.</li> <li>• Switchable CAR-T cells has been proposed to be able to control the toxicity of CAR-T, cytokine release syndrome, by optimizing the dose of the probe, but has not been shown to control on-target off-tumor toxicity of CAR-T cells.</li> <li>• Probe &amp; Catch CAR-T, Ticaros’ novel switchable CAR platform, has been applied to anti-CD40 CAR-T cells, and excellent therapeutic efficacy without on-target off-tumor toxicity has been observed.</li> <li>• Thus, Ticaros’ anti-CD40 Probe &amp; Catch CAR-T is expected to be a safe and effective CAR-T drug for blood tumors otherwise untargetable.</li> </ul>
Development Stage	Candidate
Route of Administration	A patent application will be submitted soon